The objective was to retrospectively characterise the efficacy of memantine as preventive therapy in a series of patients with frequent migraine. Patients in a university headache clinic completed a survey regarding their experience with memantine, and medical records were reviewed. All patients who received memantine as preventive therapy for migraine over a 15-month period were mailed surveys and consent forms for record review. Patients were treated with memantine beginning at a dose of 5 mg/day, increasing if needed by 5 mg/week up to 10 mg twice a day. The majority of patients (36 out of 54) treated with memantine for at least 2 months reported a significant reduction in estimated headache frequency, and improved function. Side effects were uncommon and generally mild. This limited retrospective case review suggests that memantine may be an effective preventive therapy for patients with frequent migraine. A prospective trial is warranted.
Introduction
Despite the existence of multiple well established migraine preventive therapies, there is a significant proportion of migraine patients for whom currently available therapies are either ineffective or poorly tolerated. Migraine is increasingly viewed as an episodic disorder of brain excitability. Signalling by glutamate, the primary excitatory neurotransmitter in the central nervous system, is therefore an appealing target for migraine therapy [1] . NMDA receptor antagonists are known to inhibit cortical spreading depression (CSD), which is believed to be a fundamental mechanism of migraine. Memantine is a low-affinity, open channel blocker of NMDA receptor channels that is FDA approved in the United States for the treatment of Alzheimer's disease [2, 3] . We have used memantine to treat patients with headache, the majority of whom had failed standard acute and preventive therapy. This report describes the initial experience of our patients with memantine as a treatment for prevention of migraine.
Methods
Patients were independently evaluated and treated by one of three different neurologists (AC, CF or KCB). A diagnosis of migraine was made based on ICDH-II criteria. A significant number had additional diagnoses of chronic migraine or medication overuse headache that were not considered independently of the migraine diagnosis. Patients were treated with memantine beginning at a dose of 5 mg once a day, increasing by 5 mg/week to as much as 10 mg twice a day. Patients were maintained at the lowest dose at which they were satisfied with the reduction in headache frequency. Most patients were provided medication samples to initiate therapy; some patients whose health insurance covered the cost of the medication were written a prescription to obtain the medication at a pharmacy. UCLA IRB approval was obtained to perform a retrospective case review. All migraine patients who had received memantine for at least 2 months were mailed a one-page survey, as well as a consent form to authorise review of medical records and anonymous reporting of their experience. Most patients based their responses on a headache diary, but these were not required for inclusion in the case review; headache frequencies are therefore estimates that may be significantly confounded by recall bias.
Results
Surveys and consents were mailed to 71 migraine patients who had been treated with memantine -of these 60 responded. Patient ages ranged from 14 to 78 years (mean age 49, median age 52); 49 were females and 11 were males. Twenty had migraine with aura and 40 had migraine without aura according to ICDH-II criteria. All patients had previously tried multiple approaches to migraine treatment without success. Out of 60 patients, 56 had tried other standard preventive therapies, and 51 had tried at least 2 different classes of preventive therapy.
Out of 60 patients, 54 continued therapy with memantine for at least 2 months, with ultimate doses of 5 mg, 10 mg, 15 mg and 20 mg (1, 7, 1 and 45 patients, respectively). In this group, estimated monthly headache frequency prior to memantine therapy ranged from 4 to 30 (median 12.5, mean±SD 15.2±8.8). Estimated monthly headache frequency during memantine therapy ranged from 0 to 22 (median 3.5, mean 6.1±6.0) (Fig. 1) . Out of 54 patients, 36 (67%) reported a greater than 50% reduction in estimated monthly headache frequency. The majority of patients also reported decreased headache severity, reduced amount of medication taken for headache and improved level of function (Fig. 1) . Out of 9 patients with daily headache, 6 reported a greater than 50% reduction in headache. Out of 20 patients with migraine with aura, 16 reported that it reduced the frequency of aura as well as headache. Out of 60 patients, 45 reported no side effects. Reported side effects included agitation, confusion, dizziness, weight loss, fatigue, rash and increased headache. Six patients discontinued memantine before 1 month of therapy because of side effects [rash (1), agitation (2), cognitive dysfunction (1), extremity pain (1)] and/or lack of efficacy (4).
Discussion
Our results suggest that memantine can be an effective therapy for prevention of migraine in patients in whom other established migraine preventive therapies have failed. Patients in this study had a high baseline headache frequency, and most had tried at least two standard migraine preventive therapies. Even in this population, the majority of patients had a meaningful reduction in headache frequency and severity. Memantine was generally well tolerated, although side effects resulted in discontinuation of the medication in approximately 10% of patients.
Memantine's pharmacological characteristics suggest that it has the capacity to block excessive activation of NMDA receptors without affecting normal signalling by the receptor [4] . Memantine, like other NMDA antagonists, has been found to modulate CSD [5] . It is therefore possible that memantine could reduce episodic increases in cortical excitability underlying migraine. This potential mechanism is supported by our observation that memantine reduced the frequency of aura as well as headache. Memantine also blocks other ligand gated ion channels, including nicotinic acetylcholine receptors and 5HT3 receptors [6, 7] . It could therefore have multiple other mechanisms of action that may modulate migraine.
This study is limited by its retrospective observations, lack of control group and lack of blinding. There are multiple biases that could therefore confound these observations, and there could be a highly significant placebo effect. Nonetheless, the results are encouraging because of the patient population that was studied, the overall tolerability of the medication and the scientific rationale for a mechanism of action in migraine prevention. Our patients' experience indicates that a formal prospective study of memantine's efficacy as a migraine preventive agent is warranted. Studies are ongoing in our laboratory to investigate potential cellular and pharmacological mechanisms of memantine in experimental models.
